Anna Cameron Email & Phone Number

Anytown, Ca, Us

Paris, France, Fr

Paris, France, Fr

Dublin, Ireland, Ie

Brentford, Middlesex, Gb

New York, New York, Us

Provided custom and syndicated consulting services to create and successfully implement global market access and commercial strategies for biopharmaceutical assets. Specialize in global market access and US Managed Markets strategies across Oncology, including Hematology, and Specialty Therapeutic areas.

Lawrence Township, Nj, Us

In coordination with all relevant functions and geographies, lead development of annual Market Access strategy and tactical planning for I/O product EMPLICITI to drive accelerated reimbursement while maintaining asset value. 

Lawrence Township, Nj, Us

With Alliance partner, led development / communication of unified Global Payer Access strategy, value messages and resources for ELIQUIS. Effectively navigated matrix across Alliance to develop/ maintain relationships with HEOR, Market Access colleagues, therapeutic area Development Teams, and other key stakeholders.- Led Alliance (BMS/Pfizer) Market Access Team supporting global access efforts and payer negotiations achieving Access on time or ahead of plan >90% of markets while consistently implementing pricing GOA- Developed additional LCM opportunity which achieved Faster WW Patient Access while maintaining asset value through clear well researched strategy and flawless/disciplined local implementation- Leveraged real-world, HECON data and LCM opportunity to gain preferred status with National payers in France (AFiB), UK NICE, SMC, Quebec, and gain GBA reimbursement for VTE extended treatment w/out added benefit.- Supported CV development team and partnered cross-functionally with other HEOR and commercial sub-teams.- Built/maintained solid command of external trends through advisory boards, conferences, relationships, and competitive intelligence. Synthesize with input from Medical Affairs, Health Economic & Outcomes Research, Regional Access, and Market Research to analyze trends or changes impacting current /future Market Access

Managed team of 3 Marketing Managers, consultants, and cross functional support staff to develop the Business to Business Strategy, Go-to-Market framework, reimbursement strategy and partnerships with Hospitals to secure implementation of an outcome study for technology balanced service which seeks to help Hospitals reduce CMS penalties associated with Hospital 30-day readmissions. Co-led completion of detailed P&LConceptualized and completed business plan supporting US Hospital Transitions-in-Care (HTiC) service business; secured corporate venturing funding for 2011, and implemented according to critical success factors by phase gate. •Secured and on-boarded internal resources and external partners to support business plan pilot.Led cross functional team of 3 direct reports, extended support staff, external partners (IBM) and Vendors (HMI, Telerx) to pilot the concept by building the Service, securing customers for a pilot, and creating a clinical program to measure its effectiveness, while securing IRB approval at three hospitals -- in 9 months•Leveraged Merck network to register Service as Merck’s first Class 1 Medical Device through Merck Regulatory •Directed development of Service Life Cycle Plan which was aligned pertinent aspects of the Accountable Care Act•Led Service Reimbursement Framework, Public Policy, and UNC Outcome Study supporting Merck's first corporate venturing initiative US Hospital Transition-in-Care (HTiC) Service •Developed payer validation and reimbursement framework for Hospitals and Health Plans•Oversaw pricing strategy development: Initiated and led development of positive OIG opinion supporting Service Business model and Pricing•Managed development of Hospital and GPO discount strategy, contracting framework, process, and compliance.•Ensured team activities aligned with customer needs, complex FDA and commercial legal regulations

•Led cross functional team to develop a competitive Global market access strategy framework for Hypertension Compound aimed at delivering product differentiation to the most relevant payers•Achieved Payer and Marketing alignment using Value and Label as Driver (VLAD) process and Stage 0/Phase 2B Global Market Access review resulting in payer value proposition, market access strategy including HTA needs, and market access forecast assumptions•Payer Value Proposition included, but not limited to, clinical endpoints, comparator, outcome measures, QOL instruments and HECON data.

Global Adherence Leader (2009 – 2010)Led team of 3 Managers/Associate Directors to develop and implement Merck's global adherence capability which is focused on ensuring patients achieve an optimal clinical outcome. Approach allowed Merck to capture unrealized revenue due to medication non-adherence, as well as creating and demonstrating value for healthcare professionals, payer and HTA customers globally through improving patient outcomes and optimizing healthcare expenditures •Developed robust strategy to position Merck as a leader in developing evidenced based adherence solutions•Led business plan development, operating model and general requirements for long term success•Completed benchmarking of adherence activities through external stakeholders and associated activities•Led development of generalized adherence outcomes research plan for chronic care products through an integrated internal advisory board which included members from MRL, Global Outcomes Research, and USOR. This plan was the result of extensive collaboration and consensus building across many functions and divisions.•Created organizational awareness across Merck (Research, Franchises and markets) of the Adherence Platform through systematic outreach to gain input and support to consolidate (and hence reduce) overall vendor spending on interventions within market to rapidly build a broad experience base•Coordinated the development of new adherence-related business opportunities through partnerships with Franchise markets (UK Alliance Boots, MSD Informatics, and ID Franhise (HIV solutions))•At customer request, continued to lead contracting efforts with EmblemHealth (combination HIPNY, GHI). As a result, the commercial contract was extended through 2012, and Tier 2 formulary status of JANUVIA, JANUMET and SINGULAIR with 230,000 Connecticare members was achieved

Developed short and long term strategy for Commercial segment and Self Funded Employers to enhance profitable market access, shape benefit design, ensure appropriate utilization, and optimally place solutions to achieve revenue, income, expense, and infrastructure targets for key brands and vaccines. •Supported translation of Commercial and Employer strategy to execution as requested by Customer Sales.•Led initiatives to enhance US Payer knowledge of Medical Benefit to support Merck vaccines.•Delivered desired customer experience though aligning brand strategy with desired customer experience by improving the incorporation of the customer’s perspective in strategy and customer solution development. •At customer request, continued leading contracting with EmblemHealth (combination HIPNY, GHI). As a result, formulary position for ISENTRESS was improved without a discount and market share increased 40% (8/09).

Led team of 3 Managers/Associate Directors in the development of Managed Care brand strategies and tactics to maintain coverage of infant, adolescent and adult vaccines, and ensure profitable product access of HIV products, and achieve disease management outreach objectives for GARDASIL, ZOSTAVAX and ROTATEQ in the Commercial, Managed Medicaid, FFS Medicaid, and Medicare D segments and with Employers. •Led development (4Q07) and implementation (1Q08) of MC Disease Management outreach strategy which resulted in YTD 7/31/08 outreach of 83% to plan with full year estimated actual of 100–150%•Sponsored MVID Service Agreement (SA) Sigma project which reduced contracting time by 42%, while enhancing placement rates 7-fold. Incremental net revenue, including cost reductions associated with reduced contract time, increased by $1.61M 2008/2007. One of three MVID 2008 Merck Sigma Award Submissions.•Oversaw development (1Q08) and implementation (2Q08) of Employer strategy and tactics to enhance benefit designs for GARDASIL which resulted in 7-plans, including Humana and Aetna, changing 2009 benefit design by reducing or eliminating co-pay costs for GARDASIL for women older than 18 years of age.•Oversaw development of vaccine contracting strategies and account management at Kaiser which was 124% to plan YTD 7/31/08. Successfully renegotiated a 2 year contract for ROTATEQ and Value Based Offering for GARDASIL despite pending in-class competition and numerous supply issues for other Merck vaccines•At customer request, maintained contracting responsibility for EmblemHealth (GHI/HIPNY). As a result, the formulary status of SINGULAIR was improved and MAXALT (tablets and MLT) were added to the GHI formulary enhancing NPV by $3.4M (PI 3.4) and $0.3M (PI 1.8), respectively•Recipient: 2007 Managed Care Inspire Award, Winner 2007 Marketing Award for Best Managed Care Program.

Developed account specific strategies to ensure profitable market access maximizing net sales for full Merck product line with challenging customer base. (Coventry, HIPNY, IBC, AmeriHealth Mercy Plans)•Maintained or enhanced formulary position of SINGULAIR at targeted accounts at current or reduced discounts•Achieved formulary access for JANUVIA and JANUMET in 80% of plans, PBM's, and lives w/in 6 of launch•Led Managed Medicaid Team to develop and gain Marketing approval of segment specific contracting and resource strategies for SINGULAIR, EMEND and JANUVIA enhancing/maintaining the formulary status of SINGULAIR by 35%, and achieving Tier 2 access in 80% of lives for JANUVIA at launch.•Developed and executed post-patent contracting at HIPNY resulting in 76% ZOCOR share through 12/06•Developed and executed post-patent contracting at HIPNY resulting in 76% ZOCOR share through 12/06•2006 Managed Care Rookie of the Year; Finalist 2006 Marketing Awards Best Managed Care program

Led franchise team of 4 Marketing Managers/Associate Directors in the development of market and customer segmentation strategy, promotional resources, medical education and clinical research initiatives for COZAAR/HYZAAR and developmental compounds resulting in annual sales in excess of $1.5B within the US.•Directed the creative development of direct and indirect selling resources and ensured successful field sales implementation for Quality Customer Selling (QCS) and Forward Segmentation (2005). •Developed plan and obtained approval to reallocate excess selling capacity to COZAAR/HYZAAR in 2005 and 2006 and worked with sales teams to achieve market share stabilization in 2005 and first half 2006.•Worked with Merck Research Labs to outline Clinical Development Plans and Sequence Growth opportunities. •U.S. working member of the HTN Global Marketing and Worldwide Business Strategy teams.•Worked with the Medicaid team to develop new competitive pricing which resulted in COZAAR being maintained on 90% of state PDLs (incl. 18 of the 20 largest states) saving $65M in net sales.•Developed Medicare D contracting strategy for COZAAR/HYZAAR gaining profitable access on 10 of 10 PDP's•Worked with VA/DOD team to develop pricing strategy which won the VA National ARB solicitation and oversaw marketing initiatives supporting immediate contract execution increasing market share three fold. •Finalist for 2004 Merck Marketing Awards: US and Worldwide Sequence Growth, Best Innovation.•Finalist for 2005 Merck Marketing Awards: Worldwide Franchise of the Year.

Responsible for development and execution of scientific, clinical strategies to support the launch of EMEND.•Led development and execution of scientific and promotional strategies from Phase 2 to launch.•Collaborated with Merck Research Labs, Global Team and various committees to outline clinical development plan, develop and negotiate PI and PPI for EMEND and address Phase IV commitments. •NDA submission and FDA approval achieved ahead of plan due to aggressive clinical program management.•Completed initial Statement of Interest (SOI) for EMEND IV. •Led MMD activities for innovative packaging and ensured product availability 10 days post approval.•Completed market assessment and developed strategy for entering the Oncology market.•Led successful organizational sell-in, deployment, training, strategic/tactical direction for Oncology Health Science Associates, a new sales team established for the Oncology Franchise Business Unit. •Successfully led activities for Business Plan, Profit Plan in 2000 and 2001.•Collaborated with Public and Economic Affairs, to develop preliminary pricing and reimbursement strategies.•Finalist Merck Marketing Awards: Best Physician Program, Lifecycle Management, Product Planning.

Managed 13 Representatives calling on Primary Care and Specialty physicians to achieve above plan performance of 102% and 101% in 1998 and 1999, respectively. •Successfully launched SINGULAIR. District sales and market share performance highest in Region.•Successfully launched VIOXX. District market share highest in Region and fourth in Region Business Group•Recipient Most Valuable Peer Award in 1998 and 1999.

Developed marketing and promotional strategies to support revenue growth of PRINIVIL/PRINZIDE which resulted in meeting or exceeding US sales objectives in excess of $500M.

Developed marketing and promotional strategies to support launch and revenue growth of Adherence program.

Responsible for creating and implementing traditional as well as non-traditional promotional strategies and programs for PRIMAXIN and MEFOXIN. Received Management Award and Customer Hero Status.

Mba, Health Care Administration

Bs, Medical Technology

Bachelor Of Science - Bs, Clinical Laboratory Science/Medical Technology/Technologist

Bachelor Of Science - Bs, Clinical Laboratory Science/Medical Technology/Technologist